Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canadian lab extends diagnosis capacity:

This article was originally published in Clinica

Executive Summary

Canada's National Microbiology Laboratory (NML) has received its second shipment of biosafety level 4 viruses. The delivery, from Maryland, US, includes more than a dozen reference virus strains. The NML, which specialises in diagnosis and research on what are billed by Health Canada as "some of the world's most dangerous infectious diseases", is located at the Canadian Science Centre for Human and Animal Health, in Winnipeg. The centre is the first facility in the world to accommodate both human and animal health facilities at the highest level of biocontainment, allowing researchers from both the NML and the National Centre for Foreign Animal Disease to collaborate on research into diseases affecting both humans and animals. The NML received its first shipment of biosafety level 4 viruses in June 2000.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts